tirzepatide weight loss clinical trial New trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss At a glance factsheet: Tirzepatide

The baby formula MDL consolidated several cases from across the country involving children who suffered health problems after consuming contaminated infant formula manufactured at Abbotts Sturgis, Michigan, plant

Sleep and stress management Cortisol, the stress hormone, directly opposes many of the metabolic benefits tirzepatide provides

Its unique feature is the combined effect on both receptor types, which may lead to more significant effects on glucose control and weight management

Consequently, seeing a reduction in risk of cardiovascular events is promising, albeit not surprising. Jackie DesJardin, MD, a cardiologist and an assistant clinical professor of medicine at the University of California San Franciscos Division of Cardiology, cautioned that there may be more to these results than simply the medications

Tirzepatide is a synthetic peptide developed for laboratory and scientific research